12 May 2021

Drug repurposing trends and strategic approaches for shortening timelines

PDF 5.7 MB

As the complexity of drug development increases, so does the industry’s focus on strategies and solutions that can help bring advanced products to market as quickly as possible. Lowering the cost of R&D is also a key factor, as new chemical entities and de novo drugs in clinical phases face high attrition rates, with companies losing significant investments in nonviable candidates. One approach to avoiding this fate is drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications. Understanding drug repurposing, how it can significantly reduce your time to market, and the important role established and knowledgeable CDMOs can play in this journey is critical to finding success with this emerging strategy.

Content provided by our supplier

Thermo Fisher Scientific Inc.

  • US
  • 2015
    On CPhI since
  • 5000+

Other Content from Thermo Fisher Scientific Inc.